Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Location
Wilmington, DE
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442% % -52%
Debt-to-equity 43% % 110%
Return On Equity -121% % -81%
Return On Assets -85% % -53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62,865,270 shares 14%
Entity Public Float $66,100,000 USD -14%
Weighted Average Number of Shares Outstanding, Basic 76,132,337 shares 0.36%
Weighted Average Number of Shares Outstanding, Diluted 76,132,337 shares 0.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $6,500,000 USD 117%
Research and Development Expense $107,928,000 USD -7.5%
General and Administrative Expense $23,621,000 USD -20%
Operating Income (Loss) $121,049,000 USD 16%
Net Income (Loss) Attributable to Parent $111,772,000 USD 15%
Earnings Per Share, Basic -1 USD/shares 17%
Earnings Per Share, Diluted -1 USD/shares 17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $47,532,000 USD 327%
Marketable Securities, Current $7,425,000 USD -95%
Assets, Current $58,330,000 USD -63%
Property, Plant and Equipment, Net $5,531,000 USD -23%
Operating Lease, Right-of-Use Asset $27,549,000 USD -5.6%
Assets $94,755,000 USD -52%
Accounts Payable, Current $2,533,000 USD -57%
Employee-related Liabilities, Current $6,485,000 USD -15%
Accrued Liabilities, Current $12,930,000 USD -4.8%
Liabilities, Current $18,190,000 USD -18%
Operating Lease, Liability, Noncurrent $15,127,000 USD -1.8%
Other Liabilities, Noncurrent $2,904,000 USD -7.9%
Liabilities $36,221,000 USD -11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,000 USD -99%
Retained Earnings (Accumulated Deficit) $666,604,000 USD -20%
Stockholders' Equity Attributable to Parent $58,534,000 USD -63%
Liabilities and Equity $94,755,000 USD -52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,231,000 USD -7.7%
Net Cash Provided by (Used in) Financing Activities $160,000 USD
Net Cash Provided by (Used in) Investing Activities $62,186,000 USD 99%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $27,795,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50,767,000 USD 234%
Deferred Tax Assets, Valuation Allowance $182,642,000 USD 24%
Deferred Tax Assets, Gross $187,657,000 USD 23%
Operating Lease, Liability $17,854,000 USD 0.43%
Payments to Acquire Property, Plant, and Equipment $47,000 USD -84%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $111,937,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid $39,456,000 USD -6.3%
Property, Plant and Equipment, Gross $12,025,000 USD 10%
Operating Lease, Liability, Current $2,727,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,047,000 USD 2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,973,000 USD 8.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,602,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,124,000 USD 2.3%
Deferred Tax Assets, Operating Loss Carryforwards $81,520,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,202,000 USD 2.3%
Operating Lease, Payments $620,000 USD
Depreciation, Depletion and Amortization $435,000 USD 2.1%
Deferred Tax Assets, Net of Valuation Allowance $5,015,000 USD 0.04%
Share-based Payment Arrangement, Expense $13,843,000 USD -41%